Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Tg Therapeutics (TGTX) over the last 9 years, with Q3 2025 value amounting to $80000.0.

  • Tg Therapeutics' Capital Expenditures rose 23333.33% to $80000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $168000.0, marking a year-over-year increase of 60000.0%. This contributed to the annual value of $45000.0 for FY2024, which is N/A changed from last year.
  • Tg Therapeutics' Capital Expenditures amounted to $80000.0 in Q3 2025, which was up 23333.33% from $42000.0 recorded in Q2 2025.
  • Over the past 5 years, Tg Therapeutics' Capital Expenditures peaked at $175000.0 during Q2 2021, and registered a low of $3000.0 during Q4 2022.
  • Its 4-year average for Capital Expenditures is $50583.3, with a median of $33500.0 in 2025.
  • As far as peak fluctuations go, Tg Therapeutics' Capital Expenditures skyrocketed by 28888.89% in 2021, and later crashed by 9625.0% in 2022.
  • Quarter analysis of 4 years shows Tg Therapeutics' Capital Expenditures stood at $80000.0 in 2021, then plummeted by 96.25% to $3000.0 in 2022, then surged by 600.0% to $21000.0 in 2024, then surged by 280.95% to $80000.0 in 2025.
  • Its Capital Expenditures stands at $80000.0 for Q3 2025, versus $42000.0 for Q2 2025 and $25000.0 for Q1 2025.